DOCSLIB.ORG

Pituitary Adenylate Cyclase Activating Polypeptide Signaling Alters Gene Expression in Chick Ciliary Ganglion Neurons

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pituitary Adenylate Cyclase Activating Polypeptide Signaling Alters Gene Expression in Chick Ciliary Ganglion Neurons Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Sciences Pituitary Adenylate Cyclase Activating Polypeptide Signaling Alters Gene Expression In Chick Ciliary Ganglion Neurons Submitted by: Adriane D. Sumner In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences Examination Committee Major Advisor: Joseph Margiotta, Ph.D. Academic Linda Dokas, Ph.D. Advisory Committee: David Giovannucci, Ph.D. Marthe Howard, Ph.D. Phyllis Pugh, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: January 22, 2008 Pituitary Adenylate Cyclase Activating Polypeptide Signaling Alters Gene Expression In Chick Ciliary Ganglion Neurons Adriane D. Sumner University of Toledo College of Medicine 2008 ACKNOWLEDGEMENTS I would like to thank my major advisor, Dr. Joseph Margiotta, and the other members of my advisory committee, Dr. Phyllis Pugh, Dr. Linda Dokas, Dr. Marthe Howard, and Dr. David Giovannucci, for their advice and support during my graduate education. I would like to thank the members of my lab; Dr. Gail Adams, whose help made the microarray experiments possible, Dr. Phyllis Pugh, who designed the primers used in the PAC1 splice variant and VPAC receptor conventional RT-PCR experiments, and Selwyn Jayakar, who has not only been a valuable colleague but a wonderful friend. I am very thankful for the love and support of my family and friends. I am especially grateful to my mom, Pat Sumner, and my sister, Erin Barthel, for all of those long talks and words of encouragement which sustained me through the tough times. I would never have made it without them. ii TABLE OF CONTENTS Acknowledgements ii Table of Contents iii Introduction 1 Literature 6 Methods and Materials 25 Results 38 Discussion 77 Conclusions 89 References 90 Abstract 108 iii INTRODUCTION Neuropeptides often co-localize to the same presynaptic terminals as conventional neurotransmitters and have been shown to modulate neurotransmitter functions as well as influence neuronal development and regulation (Hokfelt et al. 2000). The neuropeptide, PACAP (Pituitary adenylate cyclase-activating polypeptide), is known to be present throughout the central nervous system (CNS), the peripheral nervous system (PNS), and even in some peripheral organs (Peeters et al. 2000) and has been implicated in a wide range of biological functions (Vaudry et al. 2000). PACAP can bind to three types of G protein-coupled receptors (GPCRs); VPAC1, VPAC2, and PAC1. The VPAC1 and VPAC2 receptors have an equal affinity for both PACAP and its most closely related peptide, vasoactive intestinal peptide (VIP) which shares 68% sequence identity with PACAP. However, PAC1 is a specific PACAP receptor with a 100-1000 fold greater affinity for PACAP than for VIP (Vaudry et al. 2000). PAC1 is also known to have a number of splice variants, the majority of which result from inclusion or exclusion of exons in the N-terminal domain which determines ligand binding specificity and/or the third intracellular loop which determines the G-protein or ion channel to which the receptor will couple (Lutz et al. 2006). Previous studies from this laboratory have demonstrated that PACAP is present in the chick parasympathetic ciliary ganglion (CG) at developmental stages from embryonic day 8 (E8) through E20 (Margiotta and Pardi 1995; Pugh and Margiotta 2006). However, its location within the CG is unknown. While the presence of PAC1 receptors has also been established, it is still unknown if VPAC1 or VPAC2 are present in the chick CG. 1 This laboratory has also demonstrated that application of exogenous PACAP results in activation of PAC1 receptors leading to increased signaling through adenylate cyclase (AC) and phospholipase C (PLC), resulting in increased cAMP production and 2+ intracellular calcium (Ca in) respectively (Margiotta and Pardi 1995; Pardi and Margiotta 1999). In the chick CG, PACAP has been shown to have temporally diverse effects, exerting both gradual, survival-promoting trophic actions (Pugh and Margiotta 2006) and rapid-onset neuromodulatory effects impacting nicotinic receptors and synapses (Margiotta and Pardi 1995; Pardi and Margiotta 1999). Neuronal survival in the CG is influenced by preganglionic synaptic transmission, innervation of postganglionic targets, and neurotrophins (Nishi and Berg 1981a; Nishi and Berg 1981b). Most CG neurons do not survive when maintained in a basal culture medium lacking tissue extracts over a period of seven days (Landmesser and Pilar 1974a). However, this laboratory has demonstrated that the percentage of neurons that survive increases to approximately 70% when the culture medium is supplemented with exogenous PACAP (Pugh and Margiotta 2000). The fact that the concentration of PACAP levels off during the period of cell death in the CG suggest that PACAP plays an important role in neuronal survival in vivo as well. The neurotrophic properties of PACAP in the CG are dependent upon the AC signaling cascade involving both cAMP and PKA and by the mitogen-activated protein kinase (MAPK) signaling pathway which involves the phosphorylation of MAPK by MEK, but not the PLC signaling cascade (Pugh and Margiotta 2006). 2 The neuromodulatory actions of PACAP are rapid, occurring in most cases within minutes (Pardi and Margiotta 1999). In CG neurons, PACAP signaling rapidly influences the function of both -bungarotoxin- ( Bgt-) sensitive nicotinic acetylcholine receptors, containing only 7 subunits ( 7-nAChRs), and heteropentameric receptors, containing 3, 5, 4, and, in some cases, 2 subunits ( 3*-nAChRs) (Vernallis et al. 1993; Nai et al. 2003) which underlie normal ganglionic neurotransmission (Zhang et al. 1994; Wilson Horch and Sargent 1995). Specifically, after brief PACAP treatment (10- 60 min), both 7-nAChR and 3*-nAChR-mediated whole-cell currents recorded from CG neurons markedly increase, an effect requiring PAC1 receptors and a signal cascade triggering AC activation, cAMP accumulation, and PKA phosphorylation (Margiotta and Pardi 1995). The net nAChR modulation likely depends on an interplay between AC and PLC activation since after blocking AC with 2‟5‟-dideoxyadenosine (ddA), PACAP treatment rapidly leads to selective inhibition of 7-nAChR currents by a PLC-dependent 2+ process requiring inositol phosphate (IP) turnover and increased Ca in that leaves 3*- nAChR currents unaffected (Margiotta and Pardi 1995; Pardi and Margiotta 1999). Relevant to synaptic interactions, exposure to PACAP enhanced activity at synapses that form between CG neurons in culture, utilizing PAC1 -, AC-, cAMP- and PKA-dependent processes to increase both the frequency and amplitude of nAChR-mediated spontaneous excitatory synaptic currents (sEPSCs) by 400% and 50%, respectively (2004 Abstract and Pugh and Margiotta, unpublished). While these changes in synaptic function occur within minutes of PACAP application, they were sustained for up to 48 hours following a single 15 min exposure (Pugh and Margiotta, unpublished). These results demonstrate 3 that PACAP actions have long term consequences on both trophic and modulatory functions which could result from alterations in gene expression. This theory is further supported by the fact that changes in intracellular calcium, cAMP, and MAPK, which are observed in response to PACAP, have all previously been linked to the regulation of gene transcription as well (Squire et al. 2003). Therefore, in this study, the ability of PACAP to alter gene expression was explored. Immunostaining and microscopy techniques were used to examine the ability of PACAP to phosphorylate and activate the transcription factor CREB (cAMP/Ca2+ response element binding protein) and microarrays were used to investigate the global effect PACAP has on altering gene transcription. The activation of the transcription factor CREB was characterized as a marker for gene expression since CREB has previously been implicated in neuronal plasticity and survival and has been shown to be activated by increased levels of intracellular calcium, cAMP, and MAPK (Bito and Takemoto 2003). In this study, it is demonstrated that application of exogenous PACAP results in the phosphorylation of CREB at Ser133 in a time- and concentration-dependent manner, an effect that persists for at least 90 minutes after only a 15 min exposure to PACAP. The ability of PACAP to activate CREB requires PAC1 since it was mimicked by the PAC1 selective agonist, maxadilan, inhibited by the PAC1 antagonist, PACAP(6- 38), and showed an expected increase in the EC50 of the concentration curve when induced by VIP. PKA may play a role in the intracellular signaling cascade since two pharmacological blockers of PKA, H89 and KT5720, inhibited PACAPs ability to phosphorylate CREB. 4 It was also examined whether varying PACAP exposure regimens result in recruitment of unique or overlapping sets of genes. Using the Affymetrix (Affymetrix inc., Santa Clara, CA) 28K chicken genome array it was demonstrated that brief (15min), intermediate (24h), and chronic (96h) treatment with exogenous PACAP differentially alters gene expression in E8 CG neurons maintained in cell culture for four days. Analysis with Genesifter revealed 672 known genes regulated by PACAP including genes implicated in synaptic function, neuronal growth, survival, and development. Each PACAP treatment condition altered a unique set of genes. However, 9 genes were up- regulated and 2 genes were down-regulated in all three PACAP treatment
Load more

Recommended publications
  • ZMYND10 Functions in a Chaperone Relay During Axonemal Dynein Assembly
    bioRxiv preprint doi: https://doi.org/10.1101/233718; this version posted December 13, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 ZMYND10 functions in a chaperone relay during axonemal dynein assembly. 2 3 Girish R Mali1,9 , Patricia Yeyati1, Seiya Mizuno2, Margaret A Keighren1, Petra zur Lage3, Amaya 4 Garcia-Munoz4, Atsuko Shimada5, Hiroyuki Takeda5, Frank Edlich6, Satoru Takahashi2,7, Alex von 5 Kreigsheim4,8, Andrew Jarman3 and Pleasantine Mill1,*. 6 7 1. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of 8 Edinburgh, Edinburgh, UK, EH4 2XU 9 2. Laboratory Animal Resource Centre, University of Tsukuba, Tsukuba, Japan, 305-8575 10 3. Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK, EH8 9XD 11 4. Systems Biology Ireland, University College Dublin, Dublin, Ireland 12 5. Department of Biological Sciences, University of Tokyo, Tokyo, Japan, 113-0033 13 6. Institute for Biochemistry and Molecular Biology, University of Freiburg, Freiburg, Germany, 14 79104 15 7. Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba, 16 Japan, 305-8575 17 8. Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University 18 of Edinburgh, Edinburgh, UK, EH4 2XU 19 9. Current address: MRC Laboratory of Molecular Biology, Cambridge, UK, CB2 0QH 20 * Corresponding author: [email protected] 21 22 23 24 25 26 27 28 29 30 31 1 bioRxiv preprint doi: https://doi.org/10.1101/233718; this version posted December 13, 2017.
    [Show full text]
  • Supplemental Table S1
    Entrez Gene Symbol Gene Name Affymetrix EST Glomchip SAGE Stanford Literature HPA confirmed Gene ID Profiling profiling Profiling Profiling array profiling confirmed 1 2 A2M alpha-2-macroglobulin 0 0 0 1 0 2 10347 ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7 1 0 0 0 0 3 10350 ABCA9 ATP-binding cassette, sub-family A (ABC1), member 9 1 0 0 0 0 4 10057 ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1 0 0 0 0 5 10060 ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 1 0 0 0 0 6 79575 ABHD8 abhydrolase domain containing 8 1 0 0 0 0 7 51225 ABI3 ABI gene family, member 3 1 0 1 0 0 8 29 ABR active BCR-related gene 1 0 0 0 0 9 25841 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 1 0 1 0 0 10 30 ACAA1 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiol 0 1 0 0 0 11 43 ACHE acetylcholinesterase (Yt blood group) 1 0 0 0 0 12 58 ACTA1 actin, alpha 1, skeletal muscle 0 1 0 0 0 13 60 ACTB actin, beta 01000 1 14 71 ACTG1 actin, gamma 1 0 1 0 0 0 15 81 ACTN4 actinin, alpha 4 0 0 1 1 1 10700177 16 10096 ACTR3 ARP3 actin-related protein 3 homolog (yeast) 0 1 0 0 0 17 94 ACVRL1 activin A receptor type II-like 1 1 0 1 0 0 18 8038 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 1 0 0 0 0 19 8751 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 1 0 0 0 0 20 8728 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 1 0 0 0 0 21 81792 ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1 0 0 0 0 22 9507 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1
    [Show full text]
  • Comparison of Gene Expression Profiles in Chromate Transformed BEAS-2B Cells
    Comparison of Gene Expression Profiles in Chromate Transformed BEAS-2B Cells Hong Sun1, Harriet A. Clancy1, Thomas Kluz1, Jiri Zavadil2, Max Costa1* 1 Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York, United States of America, 2 Department of Pathology, NYU Cancer Institute and Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, New York, United States of America Abstract Background: Hexavalent chromium [Cr(VI)] is a potent human carcinogen. Occupational exposure has been associated with increased risk of respiratory cancer. Multiple mechanisms have been shown to contribute to Cr(VI) induced carcinogenesis, including DNA damage, genomic instability, and epigenetic modulation, however, the molecular mechanism and downstream genes mediating chromium’s carcinogenicity remain to be elucidated. Methods/Results: We established chromate transformed cell lines by chronic exposure of normal human bronchial epithelial BEAS-2B cells to low doses of Cr(VI) followed by anchorage-independent growth. These transformed cell lines not only exhibited consistent morphological changes but also acquired altered and distinct gene expression patterns compared with normal BEAS-2B cells and control cell lines (untreated) that arose spontaneously in soft agar. Interestingly, the gene expression profiles of six Cr(VI) transformed cell lines were remarkably similar to each other yet differed significantly from that of either control cell lines or normal BEAS-2B cells. A total of 409 differentially expressed genes were identified in Cr(VI) transformed cells compared to control cells. Genes related to cell-to-cell junction were upregulated in all Cr(VI) transformed cells, while genes associated with the interaction between cells and their extracellular matrices were down-regulated.
    [Show full text]
  • Supplementary Materials Functional Characterization of Rare RAB12
    1 Supplementary materials Functional characterization of rare RAB12 variants and their role in musician’s and other dystonias Eva Hebert et al. Figure S1. Photograph of Individual L-10289 (mildly affected mother of the index patient from Family D) showing a 15-degree tilt of the trunk to the right as well as dystonic posturing of the right hand (involuntary flexion of the third to fifth finger and thumb and extension of the index finger). 2 Figure S2. TFRC colocalized with wildtype and mutant FLAG-RAB12. Immunofluorescent staining of fibroblasts expressing FLAG-RAB12 WT, p.Gly13Asp, or p.Ile196Val revealed predominant perinuclear localization of TFRC (red) which overlaps with the localization of FLAG-RAB12 (green) in all three cell lines (WT, p.Gly13Asp, p.Ile196Val). The nucleus was stained with DAPI (blue). Scale bar: 20µm. 3 Figure S3. Lysosomal degradation of the physiological dimeric TFRC was not affected by the RAB12 mutations. Western Blot analysis revealed the degradation of TFRC in patient fibroblasts with endogenous expression of RAB12 (a, b) in fibroblasts ectopically expressing FLAG-RAB12 (c, d), and in SH-SY5Y cells ectopically expressing FLAG-RAB12 (e, f). Cells were treated with Bafilomycin A1 for 24h. ß-actin served as loading control and for normalization. Bars in B, D, and F indicate means of three independent experiments ± SEM. ctrl control, WT wildtype 4 Figure S4. Relative LC3-II protein levels are marginally increased in SH-SY5Y cells overexpressing RAB12 Gly13Asp protein and p62 levels remained constant. a) Western Blot of proteins extracted from stably transfected SH-SY5Y cells. Expression of FLAG-tagged RAB12 WT equals the expression of mutated RAB12 proteins (Gly13Asp, I196Val) (lane 3, 5, 7).
    [Show full text]
  • Establishment of the Early Cilia Preassembly Protein Complex
    Establishment of the early cilia preassembly protein PNAS PLUS complex during motile ciliogenesis Amjad Horania,1, Alessandro Ustioneb, Tao Huangc, Amy L. Firthd, Jiehong Panc, Sean P. Gunstenc, Jeffrey A. Haspelc, David W. Pistonb, and Steven L. Brodyc aDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110; bDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110; cDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110; and dDepartment of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033 Edited by Kathryn V. Anderson, Sloan Kettering Institute, New York, NY, and approved December 27, 2017 (received for review September 9, 2017) Motile cilia are characterized by dynein motor units, which preas- function of these proteins is unknown; however, missing dynein semble in the cytoplasm before trafficking into the cilia. Proteins motor complexes in the cilia of mutants and cytoplasmic locali- required for dynein preassembly were discovered by finding human zation (or absence in the cilia proteome) suggest a role in the mutations that result in absent ciliary motors, but little is known preassembly of dynein motor complexes. Studies in C. reinhardtii about their expression, function, or interactions. By monitoring show motor components in the cell body before transport to ciliogenesis in primary airway epithelial cells and MCIDAS-regulated flagella (22–25). However, the expression, interactions, and induced pluripotent stem cells, we uncovered two phases of expres- functions of preassembly proteins, as well as the steps required sion of preassembly proteins. An early phase, composed of HEATR2, for preassembly, are undefined.
    [Show full text]
  • De Novo, Systemic, Deleterious Amino Acid Substitutions Are Common in Large Cytoskeleton‑Related Protein Coding Regions
    BIOMEDICAL REPORTS 6: 211-216, 2017 De novo, systemic, deleterious amino acid substitutions are common in large cytoskeleton‑related protein coding regions REBECCA J. STOLL1, GRACE R. THOMPSON1, MOHAMMAD D. SAMY1 and GEORGE BLANCK1,2 1Department of Molecular Medicine, Morsani College of Medicine, University of South Florida; 2Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA Received June 13, 2016; Accepted October 31, 2016 DOI: 10.3892/br.2016.826 Abstract. Human mutagenesis is largely random, thus large Introduction coding regions, simply on the basis of probability, represent relatively large mutagenesis targets. Thus, we considered Genetic damage is largely random and therefore tends to the possibility that large cytoskeletal-protein related coding affect the larger, functional regions of the human genome regions (CPCRs), including extra-cellular matrix (ECM) more frequently than the smaller regions (1). For example, coding regions, would have systemic nucleotide variants that a systematic study has revealed that cancer fusion genes, on are not present in common SNP databases. Presumably, such average, are statistically, significantly larger than other human variants arose recently in development or in recent, preceding genes (2,3). The large introns of potential cancer fusion genes generations. Using matched breast cancer and blood-derived presumably allow for many different productive recombina- normal datasets from the cancer genome atlas, CPCR single tion opportunities, i.e., many recombinations that would allow nucleotide variants (SNVs) not present in the All SNPs(142) for exon juxtaposition and the generation of hybrid proteins. or 1000 Genomes databases were identified. Using the Protein Smaller cancer fusion genes tend to be associated with the rare Variation Effect Analyzer internet-based tool, it was discov- types of cancer, for example EWS RNA binding protein 1 in ered that apparent, systemic mutations (not shared among Ewing's sarcoma.
    [Show full text]
  • Next Generation Massively Parallel Sequencing of Targeted
    ARTICLE Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: Implications for application to clinical testing Jonathan S. Berg, MD, PhD1,2, James P. Evans, MD, PhD1,2, Margaret W. Leigh, MD3, Heymut Omran, MD4, Chris Bizon, PhD5, Ketan Mane, PhD5, Michael R. Knowles, MD2, Karen E. Weck, MD1,6, and Maimoona A. Zariwala, PhD6 Purpose: Advances in genetic sequencing technology have the potential rimary ciliary dyskinesia (PCD) is an autosomal recessive to enhance testing for genes associated with genetically heterogeneous Pdisorder involving abnormalities of motile cilia, resulting in clinical syndromes, such as primary ciliary dyskinesia. The objective of a range of manifestations including situs inversus, neonatal this study was to investigate the performance characteristics of exon- respiratory distress at full-term birth, recurrent otitis media, capture technology coupled with massively parallel sequencing for chronic sinusitis, chronic bronchitis that may result in bronchi- 1–3 clinical diagnostic evaluation. Methods: We performed a pilot study of ectasis, and male infertility. The disorder is genetically het- four individuals with a variety of previously identified primary ciliary erogeneous, rendering molecular diagnosis challenging given dyskinesia mutations. We designed a custom array (NimbleGen) to that mutations in nine different genes (DNAH5, DNAH11, capture 2089 exons from 79 genes associated with primary ciliary DNAI1, DNAI2, KTU, LRRC50, RSPH9, RSPH4A, and TX- dyskinesia or ciliary function and sequenced the enriched material using NDC3) account for only approximately 1/3 of PCD cases.4 the GS FLX Titanium (Roche 454) platform. Bioinformatics analysis DNAH5 and DNAI1 account for the majority of known muta- was performed in a blinded fashion in an attempt to detect the previ- tions, and the other genes each account for a small number of ously identified mutations and validate the process.
    [Show full text]
  • Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma
    Research Article Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma Chunhua Lu,1 Tomas Bonome,3 Yang Li,1 Aparna A. Kamat,1 Liz Y. Han,1 Rosemarie Schmandt,1 Robert L. Coleman,1 David M. Gershenson,1 Robert B. Jaffe,4 MichaelJ. Birrer, 3 and AnilK. Sood 1,2 Departments of 1Gynecologic Oncology and 2Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas; 3Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland; and 4Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California Abstract the promise of such approaches. However, the full spectrum of Therapeutic strategies based on antiangiogenic approaches differences in the tumor vasculature compared with its normal are beginning to show great promise in clinical studies. counterpart is not known. Identification of additional targets on However, full realization of these approaches requires tumor endothelium may allow opportunities for developing new identification of key differences in gene expression between therapeutic approaches to inhibit angiogenesis in a tumor-specific endothelial cells from tumors versus their normal counter- manner. parts. Here, we examined gene expression differences in Higher levels of proangiogenic cytokines and angiogenesis are purified endothelial cells from 10invasive epithelial ovarian associated with an increased risk of metastasis and poor prognosis cancers and 5 normal ovaries using Affymetrix U133 Plus in ovarian cancer (5, 6). To date, a small number of breast, colon, 2.0microarrays. More than 400differentially expressed genes and brain cancers have been analyzed for gene expression changes were identified in tumor-associated endothelial cells.
    [Show full text]
  • Antibody List 2014
    Antibody List 2014 Office of Technology Transfer, DKFZ Terms and Conditions Terms and conditions for licensing DKFZ’s antibodies are available upon request. Disclaimer This antibody list is neither exhaustive nor qualifies as a commercial catalogue. DKFZ has prepared the contents of this list to the best of its knowledge and confirms to the best of its knowledge that the listed antibodies are created at or in cooperation with DKFZ. DKFZ does not warrant that any listed antibody is available. Moreover DKFZ does not warrant that any listed antibody and / or the use thereof is not protected by any third party rights. Contact: Office of Technology Transfer (T010) Deutsches Krebsforschungszentrum (DKFZ) German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany E-mail: [email protected] Index MMP9 AATF Hexa-His MPO ABCB5 HIP128 Myo II AID HIP150 NET1 AGO1 HIPK-2 Nephrin AuroraC HIPPI NF1 APC Histone H1.0 NM-1 (NMy1) BPAG Histone H1.2 NMUR-2 BPV1 L1 Histone H1.3 NO-52 BPV1 E7 Histone H1.4 NO-66 BTG2 HLA-DM NO-145 CCDC103 HLA-DO NPHP1 CCR4 HLA-DP NPHP3 CCR8 HLA-DQ NPHP4 CCR9 HLA-DR NPM CCR10 HPV11 L1 Nup88 CD3 HPV11 E2 Nus/S-tag CD19 HPV16 L1 OCAB CD22 HPV16 L2 ODA7 CD23 HPV16 E5 PACS-1 CD37 HPV16 E6 PACT CD53 HPV16 E7 p16 CD56 HPV18 E6 p27KIP CD71 HPV18 E7 p53 CD171 (L1CAM) HPV20 E6 Pick CEACAM1 HPV20 E7 PKD1 Cep170 HPV27 E6 PIF Densin HPV27 E7 Plasminogen acitvator (PA) DLL4 HSC70 Podocin DNAH3 HSP70 PSA DNAH5 Jade1 PSMA DNAH8 JAM4 PTEN DNAH11 Ki67 RFP2 DNAse1 KTU RGS7 DSC2 LaminA RIP140 EGFR LaminB1
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Stroke Genetics and Genomics
    Faculdade de Medicina da Universidade de Lisboa Unidade Neurológica de Investigação Clínica PhD Thesis Stroke Genetics and Genomics Tiago Krug Coelho Host Institution: Instituto Gulbenkian de Ciência Supervisor at Instituto Gulbenkian de Ciência: Doctor Sofia Oliveira Supervisor at Faculdade de Medicina da Universidade de Lisboa: Professor José Ferro PhD in Biomedical Sciences Specialization in Neurosciences 2010 Stroke Genetics and Genomics A ciência tem, de facto, um único objectivo: a verdade. Não esgota perfeitamente a sua tarefa se não descobre a causa do todo. Chiara Lubich i Stroke Genetics and Genomics ii Stroke Genetics and Genomics A impressão desta dissertação foi aprovada pela Comissão Coordenadora do Conselho Científico da Faculdade de Medicina de Lisboa em reunião de 28 de Setembro de 2010. iii Stroke Genetics and Genomics iv Stroke Genetics and Genomics As opiniões expressas são da exclusiva responsabilidade do seu autor. v Stroke Genetics and Genomics vi Stroke Genetics and Genomics Abstract ABSTRACT This project presents a comprehensive approach to the identification of new genes that influence the risk for developing stroke. Stroke is the leading cause of death in Portugal and the third leading cause of death in the developed world. It is even more disabling than lethal, and the persistent neurological impairment and physical disability caused by stroke have a very high socioeconomic cost. Moreover, the number of affected individuals is expected to increase with the current aging of the population. Stroke is a “brain attack” cutting off vital blood and oxygen to the brain cells and it is a complex disease resulting from environmental and genetic factors.
    [Show full text]
  • Supplementary File
    Supplementary file COL1A2 FZD3 1 1 HPRD HPRD Humannet Humannet 0.8 PPIwu 0.8 PPIwu 0.6 0.6 0.4 0.4 Ratio of of indegree Ratio Ratio of Indegree 0.2 0.2 0 0 0 0.05 0.1 0.15 0.2 0 0.05 0.1 0.15 0.2 Frequency Frequency RBL1 SMARCA4 1 1 HPRD HPRD Humannet Humannet 0.8 PPIwu 0.8 PPIwu 0.6 0.6 0.4 0.4 Ratio of Indegree Ratio of Indegree Ratio 0.2 0.2 0 0 0 0.05 0.1 0.15 0.2 0 0.05 0.1 0.15 0.2 Frequency Frequency SRC TP53 1 1 HPRD Humannet 0.95 0.8 PPIwu 0.9 e 0.6 0.85 0.8 0.4 Ratio of Indegree of Ratio Ratio of Indegre 0.75 0.2 HPRD 0.7 Humannet PPIwu 0 0.65 0 0.05 0.1 0.15 0.2 0 0.05 0.1 0.15 0.2 Frequency Frequency VCAN 1 HPRD Humannet 0.8 PPIwu 0.6 0.4 Ratio of Indegree 0.2 0 0 0.05 0.1 0.15 0.2 Frequency Figure S1. Variation of indegree ratio with frequency cutoffs from 0 to 0.2 with a step 0.002 for driver genes common by three fitness cores in COAD. The indegree ratio is set to NULL if total degree of this genes is less than 5. BRAF CASR 1 1 0.8 0.8 0.6 0.6 0.4 0.4 Ratio of Indegree Ratio of Indegree of Ratio HPRD HPRD 0.2 0.2 Humannet Humannet PPIwu PPIwu 0 0 0 0.05 0.1 0.15 0.2 0 0.05 0.1 0.15 0.2 Frequency Frequency HDAC9 NRAS 1 1 0.8 0.8 0.6 0.6 0.4 0.4 HPRD HPRD Ratio of Indegree Ratio of Indegree 0.2 0.2 Humannet Humannet PPIwu PPIwu 0 0 0 0.05 0.1 0.15 0.2 0 0.05 0.1 0.15 0.2 Frequency Frequency NF1 CNTNAP2 1 1 0.9 0.8 0.8 0.6 0.7 0.4 HPRD HPRD Ratio of Indegree Ratio of Indegree 0.6 Humannet 0.2 Humannet PPIwu PPIwu 0.5 0 0 0.05 0.1 0.15 0.2 0 0.05 0.1 0.15 0.2 Frequency Frequency Figure S2.
    [Show full text]